Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Chief Financial Officer | April 26, 2024 | April 29, 2024 |
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | July 01, 2024 | July 03, 2024 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 06, 2024 | June 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date April 26, 2024 · Filed April 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,637 |
Reported balance
After 2024-04-26 transaction · row 1
1 source rowRow 1 · 2024-04-26 · Grant · Acquired 12,500 · Balance 82,637 F1: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSU vests in three substantially equal annual installments on each of the first three anniversaries of September 30, 2023, subject to the Reporting Person's continued service with BEAM through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.87 · Expires 2034-04-26 | Direct | 25,000 |
Reported balance
After 2024-04-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-26 · Grant · Acquired 25,000 · Balance 25,000 F2: This stock option vests in equal monthly installments each month following July 31, 2023 for the subsequent thirty-six months, subject to the Reporting Person's continued service with BEAM through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSU vests in three substantially equal annual installments on each of the first three anniversaries of September 30, 2023, subject to the Reporting Person's continued service with BEAM through each vesting date.
F2: This stock option vests in equal monthly installments each month following July 31, 2023 for the subsequent thirty-six months, subject to the Reporting Person's continued service with BEAM through each vesting date.
RECURSION PHARMACEUTICALS, INC.
Report date July 01, 2024 · Filed July 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 71,254 |
Reported balance
After 2024-07-01 transaction · row 1
1 source rowRow 1 · 2024-07-01 · Grant · Acquired 1,843 · Balance 71,254 F1: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.
Rapport Therapeutics, Inc.
Report date June 06, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2034-01-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-06-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares underlying this option vest and become exercisable in sixteen (16) equal quarterly installments, with the first installment vested on April 13, 2024, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest and become exercisable in sixteen (16) equal quarterly installments, with the first installment vested on April 13, 2024, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2021 Filed Jul 2, 2021 22:01 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 15,000 | $117.00 | $1,755,000.00 |
DisclosureSEC source: 0000899243-21-027313 · doc4.xml · nonDerivative · entry 2 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,809 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 22:01 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 30,000 | $13.68 | $410,400.00 |
DisclosureSEC source: 0000899243-21-027313 · doc4.xml · nonDerivative · entry 1 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · derivative · entry 9 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,941 Underlying: Common Stock · 45,000 shares Expires 2029-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F10 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 19,800 | $109.41 | $2,166,318.00 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 8 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,809 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.98, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 4,803 | $108.45 | $520,885.35 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 7 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,609 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to $108.99, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,290 | $107.20 | $352,688.00 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 6 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,412 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.90, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 8,907 | $106.13 | $945,299.91 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 5 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,702 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.89, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 5,220 | $105.34 | $549,874.80 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 4 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,609 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.95, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,880 | $104.63 | $196,704.40 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 3 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,829 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.58 to $104.96, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,100 | $103.86 | $114,246.00 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 2 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,709 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.74 to $103.97, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 45,000 | $13.68 | $615,600.00 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 1 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 404,688 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-21-028020 · doc4.xml · derivative · entry 8 Burrell Terry-Ann · CIK 0001786484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,688 Underlying: Class A Common · 404,688 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after April 29, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 404,688 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-21-028020 · doc4.xml · derivative · entry 7 Burrell Terry-Ann · CIK 0001786484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 404,688 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after April 29, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028020 · doc4.xml · derivative · entry 6 Burrell Terry-Ann · CIK 0001786484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Common Stock · 12,500 shares Expires 2031-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option becomes exercisable upon the earlier of April 15, 2022 or the date of the Issuer's first annual meeting of stockholders. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028020 · doc4.xml · derivative · entry 5 Burrell Terry-Ann · CIK 0001786484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2031-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option becomes exercisable upon the earlier of April 15, 2022 or the date of the Issuer's first annual meeting of stockholders. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028020 · doc4.xml · nonDerivative · entry 4 Burrell Terry-Ann · CIK 0001786484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with all such shares being received on the earlier of April 16, 2022 or the Issuer's first annual meeting of stockholders. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028020 · doc4.xml · nonDerivative · entry 3 Burrell Terry-Ann · CIK 0001786484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with all such shares being received on the earlier of April 16, 2022 or the Issuer's first annual meeting of stockholders. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A Common Stock | 126,561 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028020 · doc4.xml · nonDerivative · entry 2 Burrell Terry-Ann · CIK 0001786484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,561 F1 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherCommon Stock | 126,561 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028020 · doc4.xml · nonDerivative · entry 1 Burrell Terry-Ann · CIK 0001786484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 23:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027394 · doc4.xml · nonDerivative · entry 1 Burrell Terry-Ann · CIK 0001786484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,561 F1 · security: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. F2 · shares: The shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with all such shares being received on the earlier of April 16, 2022 or the Issuer's first annual meeting of stockholders. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027394 · doc4.xml · derivative · entry 2 Burrell Terry-Ann · CIK 0001786484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-04-14 F3 · derivative.exercise_date: The option becomes exercisable upon the earlier of April 15, 2022 or the date of the Issuer's first annual meeting of stockholders. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:11 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $80.04 | $0.00 |
DisclosureSEC source: 0000899243-21-014610 · doc4.xml · derivative · entry 2 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-03-31 F2 · derivative.exercise_date: The stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with the Company through each vesting date. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:11 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014610 · doc4.xml · nonDerivative · entry 1 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,809 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Company's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:40 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0000899243-21-000430 · doc4.xml · derivative · entry 9 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,941 Underlying: Common Stock · 25,000 shares Expires 2029-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · derivative.exercise_date: 25% of the shares subject to the stock option vested on the first anniversary of the of the vesting commencement date, August 20, 2019, and the remaining shares shall vest in 36 substantially equal monthly installments thereafter, subject to continued service with BEAM through such dates. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:40 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 900 | $83.89 | $75,501.00 |
DisclosureSEC source: 0000899243-21-000430 · doc4.xml · nonDerivative · entry 8 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,309 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: These shares were sold in multiple transactions ranging from $83.85 to $84.01 inclusive. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:40 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 7,095 | $83.15 | $589,949.25 |
DisclosureSEC source: 0000899243-21-000430 · doc4.xml · nonDerivative · entry 7 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,209 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: These shares were sold in multiple transactions ranging from $82.80 to $83.78 inclusive. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:40 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 5,296 | $82.44 | $436,602.24 |
DisclosureSEC source: 0000899243-21-000430 · doc4.xml · nonDerivative · entry 6 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,304 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: These shares were sold in multiple transactions ranging from $81.80 to $82.79 inclusive. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:40 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 6,509 | $81.26 | $528,921.34 |
DisclosureSEC source: 0000899243-21-000430 · doc4.xml · nonDerivative · entry 5 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,600 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: These shares were sold in multiple transactions ranging from $80.73 to $81.72 inclusive. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:40 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,449 | $80.25 | $196,532.25 |
DisclosureSEC source: 0000899243-21-000430 · doc4.xml · nonDerivative · entry 4 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,109 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: These shares were sold in multiple transactions ranging from $79.73 to $80.72 inclusive. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:40 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,951 | $79.21 | $154,538.71 |
DisclosureSEC source: 0000899243-21-000430 · doc4.xml · nonDerivative · entry 3 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,558 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: These shares were sold in multiple transactions ranging from $78.72 to $79.65 inclusive. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:40 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 800 | $78.05 | $62,440.00 |
DisclosureSEC source: 0000899243-21-000430 · doc4.xml · nonDerivative · entry 2 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,509 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: These shares were sold in multiple transactions ranging from $77.65 to $78.48 inclusive. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:40 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 25,000 | $13.68 | $342,000.00 |
DisclosureSEC source: 0000899243-21-000430 · doc4.xml · nonDerivative · entry 1 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 01:08 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,309 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0000899243-20-025849 · doc4.xml · derivative · entry 2 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,941 Underlying: Common Stock · 7,309 shares Expires 2029-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the of the vesting commencement date, August 20, 2019, and the remaining shares shall vest in 36 substantially equal monthly installments thereafter, subject to continued service with BEAM through such dates. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 01:08 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 7,309 | $13.68 | $99,987.12 |
DisclosureSEC source: 0000899243-20-025849 · doc4.xml · nonDerivative · entry 1 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.